SCHEMBL19212337

SCHEMBL19212337

CC(C)(C)OC(=O)N1CCN(c2ncc(CCN)cc2Cl)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
GPR119 Q8TDV5 5/20 0.44
KIT P10721 2/20 0.44
SUV39H2 Q9H5I1 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
KDM1A O60341 1/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 1/20 0.41
P2RY12 Q9H244 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899444 0.88 MEN1 (0.54) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL30223144 0.88 MEN1 (0.54) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL29268346 0.84 MEN1 (0.50) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL3171182 0.83 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL30903367 0.83 MEN1 (0.53) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL19212199 0.83 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2LMNAMAPT
SCHEMBL2366192 0.83 MEN1 (0.55) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL28677820 0.82 GPR119 (0.39) NR1H2NR1H3GPR119SUV39H2
SCHEMBL30223154 0.82 GPR119 (0.48) MEN1KMT2ANR1H2NR1H3GPR119
SCHEMBL2419414 0.82 MEN1 (0.52) MEN1KMT2ANR1H2NR1H3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3414252-B1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO HEALTH INC (US) 2022-07-06 EP disclosed
CN-109071560-B Thienopyridine carboxamides as ubiquitin-specific protease inhibitors 瓦洛健康公司 2022-01-14 CN disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 US disclosed
EP-3414252-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 EP disclosed
WO-2017139778-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 MEN1 2229/4885KMT2A 516/4885NR1H2 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.